{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:41:37Z","timestamp":1793749297319,"version":"4.6.1"},"reference-count":131,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Conventional chemotherapy and targeted therapies have limited efficacy against advanced head and neck squamous cell carcinoma (HNSCC). The immune checkpoint inhibitors (ICIs) such as antibodies against CTLA-4, PD-1, and PD-L1 interrupt the co-inhibitory pathway of T cells and enhance the ability of CD8+ T cells to destroy tumors. Even in advanced HNSCC patients with recurrent diseases and distant metastasis, ICI therapy shows efficiency and become an effective alternative to conventional chemotherapy. However, as this therapy releases the immune tolerance state, cytotoxic CD8+ T cells can also attack organs and tissues expressing self-antigens that cross-react with tumor antigens and induce immune-related adverse events (irAEs). When patients with HNSCC are treated with ICIs, autoimmune diseases occur in multiple organs including the skin, digestive tract, endocrine system, liver, and respiratory tract. Treatment of various malignancies, including HNSCC, with ICIs may result in the appearance of oral irAEs. In the oral cavity, an oral lichenoid reaction (OLR) and pemphigoid develop. Sicca syndrome also occurs in association with ICIs, affecting the salivary glands to induce xerostomia. It is necessary to elucidate the pathogenic mechanisms of these intractable diseases that are not seen with conventional therapy. Early diagnosis and appropriate approaches to irAEs are needed for efficient treatment of advanced HNSCC by ICIs.<\/jats:p>","DOI":"10.3390\/cancers14030792","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T11:35:17Z","timestamp":1643974517000},"page":"792","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"Yoshiaki","family":"Yura","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lee, H.T., Lee, S.H., and Heo, Y.S. (2019). Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules, 24.","DOI":"10.3390\/molecules24061190"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.oraloncology.2008.05.017","article-title":"Current concepts in management of oral cancer\u2014surgery","volume":"45","author":"Shah","year":"2009","journal-title":"Oral Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12703\/P6-44","article-title":"Advances in the management of squamous cell carcinoma of the head and neck","volume":"6","author":"Machiels","year":"2014","journal-title":"F1000Prime Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2015.00256","article-title":"Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy","volume":"5","author":"Jakobi","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/osi2.1014","article-title":"Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients","volume":"16","author":"Yura","year":"2019","journal-title":"Oral Sci. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1200\/JCO.2015.61.2929","article-title":"Oral Cavity Carcinoma: Current, Controversies, and Future Directions","volume":"33","author":"Chinn","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13014-016-0630-x","article-title":"Outcomes of patients with loco-regionally recurrent or new primary squamous cell carcinomas of the head and neck treated with curative intent reirradiation at Mayo Clinic","volume":"11","author":"Curtis","year":"2016","journal-title":"Radiat. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-Oncology: Emerging Targets and Combination Therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","volume":"35","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.oraloncology.2019.06.017","article-title":"Nivolumab versus investigator\u2019s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age","volume":"96","author":"Saba","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"104525","DOI":"10.1016\/j.oraloncology.2019.104525","article-title":"Relationship between immune-related adverse events and the long-term outcomes in recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab","volume":"101","author":"Matsuo","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"vii59","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6061825","DOI":"10.1155\/2018\/6061825","article-title":"Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management","volume":"2018","author":"Saccucci","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gualtierotti, R., Marzano, A.V., Spadari, F., and Cugno, M. (2018). Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010021"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.immuni.2009.03.003","article-title":"Follicular helper T cells: Lineage and location","volume":"30","author":"Fazilleau","year":"2009","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","article-title":"Follicular helper T cells in immunity and systemic autoimmunity","volume":"8","author":"Craft","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"Bodian","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/intimm\/dxv079","article-title":"T follicular helper cells, T follicular regulatory cells and autoimmunity","volume":"28","author":"Zhu","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.4049\/jimmunol.1701231","article-title":"Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function","volume":"200","author":"Sage","year":"2018","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.intimp.2018.10.045","article-title":"PD-1 blockade augments humoral immunity through ICOS-mediated CD4(+) T cell instruction","volume":"66","author":"Zhang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Linterman, M.A., and Hill, D.L. (2016). Can follicular helper T cells be targeted to improve vaccine efficacy?. F1000Research, 5.","DOI":"10.12688\/f1000research.7388.1"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.3389\/fimmu.2018.02469","article-title":"Regulation of the Germinal Center Response","volume":"9","author":"Stebegg","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.3389\/fimmu.2017.01790","article-title":"Are Follicular Regulatory T Cells Involved in Autoimmune Diseases?","volume":"8","author":"Gong","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.it.2015.05.005","article-title":"T follicular regulatory cells in the regulation of B cell responses","volume":"36","author":"Sage","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1084\/jem.182.5.1609","article-title":"Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the brown locus protein","volume":"182","author":"Hara","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1196\/annals.1423.043","article-title":"Harnessing autoimmunity (vitiligo) to treat melanoma: A myth or reality?","volume":"1110","author":"Ram","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Burke, K.P., Grebinoski, S., Sharpe, A.H., and Vignali, D.A.A. (2021). Understanding adverse events of immunotherapy: A mechanistic perspective. J. Exp. Med., 218.","DOI":"10.1084\/jem.20192179"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab, N., Shah, M., and Suarez-Almazor, M.E. (2016). Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160221"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low\/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bbapap.2009.09.019","article-title":"Fine tuning T lymphocytes: A role for the lipid phosphatase SHIP-1","volume":"1804","author":"Parry","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1479-5876-7-35","article-title":"CTLA4 blockade increases Th17 cells in patients with metastatic melanoma","volume":"7","author":"Chodon","year":"2009","journal-title":"J. Transl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2018.08.007","article-title":"A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity","volume":"95","author":"Kumar","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.neo.2019.07.006","article-title":"Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer","volume":"21","author":"Fiegle","year":"2019","journal-title":"Neoplasia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/cas.13758","article-title":"Activation of central\/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody","volume":"109","author":"Yamaguchi","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yoshida, K., Okamoto, M., Sasaki, J., Kuroda, C., Ishida, H., Ueda, K., Ideta, H., Kamanaka, T., Sobajima, A., and Takizawa, T. (2020). Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer, 20.","DOI":"10.1186\/s12885-019-6499-y"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.4049\/jimmunol.1401936","article-title":"PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells","volume":"194","author":"Park","year":"2015","journal-title":"J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cei.13060","article-title":"In-vitro effect of pembrolizumab on different T regulatory cell subsets","volume":"191","author":"Toor","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"622442","DOI":"10.3389\/fimmu.2020.622442","article-title":"B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies","volume":"11","author":"Willsmore","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1\/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Bomze","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","author":"Das","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/ni.1790","article-title":"Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal","volume":"10","author":"Fife","year":"2009","journal-title":"Nat. Immunol"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Szumilas","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment","volume":"105","author":"Passat","year":"2018","journal-title":"Bull. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2326-6066.CIR-18-0245","article-title":"Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors","volume":"7","author":"Rozeman","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/713774061","article-title":"Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells","volume":"9","author":"Eppihimer","year":"2002","journal-title":"Microcirculation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yamauchi, I., Yasoda, A., Matsumoto, S., Sakamori, Y., Kim, Y.H., Nomura, M., Otsuka, A., Yamasaki, T., Saito, R., and Kitamura, M. (2019). Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216954"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.21037\/atm-20-6427","article-title":"The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer","volume":"9","author":"Naqash","year":"2021","journal-title":"Ann. Transl Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3389\/fimmu.2019.01235","article-title":"Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1132137","DOI":"10.1080\/2162402X.2015.1132137","article-title":"Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota","volume":"6","author":"Pitt","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/0022034520924633","article-title":"The Bacterial Connection between the Oral Cavity and the Gut Diseases","volume":"99","author":"Kitamoto","year":"2020","journal-title":"J. Dent. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-15-2001","article-title":"Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN\u03b3 That Induce PD-L1 Expression in Head and Neck Cancer","volume":"76","author":"Srivastava","year":"2016","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.oraloncology.2017.07.023","article-title":"A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator\u2019s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141","volume":"73","author":"Kiyota","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/00016489.2019.1648867","article-title":"Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study","volume":"139","author":"Okamoto","year":"2019","journal-title":"Acta Otolaryngol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Baldini","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/eos.12536","article-title":"Current concepts on Sj\u00f6gren\u2019s syndrome - classification criteria and biomarkers","volume":"126 Suppl 1","author":"Jonsson","year":"2018","journal-title":"Eur. J. Oral. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaut.2017.11.003","article-title":"Th17 cells in primary Sj\u00f6gren\u2019s syndrome: Pathogenicity and plasticity","volume":"87","author":"Verstappen","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Parisis, D., Chivasso, C., Perret, J., Soyfoo, M.S., and Delporte, C. (2020). Current State of Knowledge on Primary Sj\u00f6gren\u2019s Syndrome, an Autoimmune Exocrinopathy. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072299"},{"key":"ref_91","first-page":"271","article-title":"When B cells break bad: Development of pathogenic B cells in Sj\u00f6gren\u2019s syndrome","volume":"38","author":"Reed","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_92","first-page":"114","article-title":"Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Maria","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis","volume":"82","author":"Champiat","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1093\/annonc\/mdx531","article-title":"Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment","volume":"28","author":"Teyssonneau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e000412","DOI":"10.1136\/rmdopen-2016-000412","article-title":"Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity","volume":"3","author":"Calabrese","year":"2017","journal-title":"RMD Open"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e00322","DOI":"10.1002\/rcr2.322","article-title":"Nivolumab-induced sialadenitis","volume":"6","author":"Takahashi","year":"2018","journal-title":"Respirol. Case Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending","volume":"25","author":"Sibaud","year":"2020","journal-title":"Oncologist"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2169\/internalmedicine.4701-20","article-title":"Sj\u00f6gren\u2019s Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer","volume":"59","author":"Higashi","year":"2020","journal-title":"Intern. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-016-0924-2","article-title":"B-cell and T-cell quantification in minor salivary glands in primary Sj\u00f6gren\u2019s syndrome: Development and validation of a pixel-based digital procedure","volume":"18","author":"Costa","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-017-1385-y","article-title":"CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sj\u00f6gren\u2019s syndrome patients and correlates with focus score and disease activity","volume":"19","author":"Alessandri","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tripleo.2004.06.077","article-title":"Current controversies in oral lichen planus: Report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis","volume":"100","author":"Lodi","year":"2005","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"ref_104","first-page":"e1","article-title":"Oral lichen planus and oral lichenoid lesions: Diagnostic and therapeutic considerations","volume":"103","author":"Schifter","year":"2007","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2334\/josnusd.48.185","article-title":"Histochemical analysis of pathological alterations in oral lichen planus and oral lichenoid lesions","volume":"48","author":"Juneja","year":"2006","journal-title":"J. Oral Sci."},{"key":"ref_106","first-page":"E310","article-title":"Oral lichen planus and oral lichenoid lesions; a critical appraisal with emphasis on the diagnostic aspects","volume":"14","year":"2009","journal-title":"Med. Oral Patol. Oral Cir. Bucal."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: Clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamadermatol.2016.4443","article-title":"Severe Oral Ulcers Associated With Nivolumab Treatment","volume":"153","author":"Namiki","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/1346-8138.14205","article-title":"Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review","volume":"45","author":"Obara","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijom.2018.07.025","article-title":"Drug-induced oral lichenoid reaction during nivolumab therapy","volume":"48","author":"Enomoto","year":"2019","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/odi.13218","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series","volume":"26","author":"Shazib","year":"2020","journal-title":"Oral Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"104623","DOI":"10.1016\/j.oraloncology.2020.104623","article-title":"Nivolumab-related lichen planus of the lip in a patient with head and neck cancer","volume":"104","author":"Economopoulou","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/1735-3327.113328","article-title":"A retrospective comparative study on clinico-pathologic features of oral lichen planus and oral lichenoid lesions","volume":"10","author":"Aminzadeh","year":"2013","journal-title":"Dent. Res. J. (Isfahan)"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1634\/theoncologist.2014-0169","article-title":"Lichenoid mucosal reaction to rituximab","volume":"19","author":"Hochberg","year":"2014","journal-title":"Oncologist"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/j.oooo.2018.06.009","article-title":"Oral lichenoid reactions may possibly be associated with abatacept: A case report and literature update","volume":"126","author":"Elad","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Suter","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2340\/00015555-3185","article-title":"Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy","volume":"99","author":"Miyagawa","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000505968","article-title":"Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report","volume":"13","author":"Cardona","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_120","first-page":"167","article-title":"Immune-Related Adverse Events Mimicking Behcet\u2019s Disease in a Gastric Cancer Patient Following Camrelizumab Treatment","volume":"17","author":"Wang","year":"2020","journal-title":"Iran. J. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000260","article-title":"Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies","volume":"26","author":"Hwang","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions","volume":"43","author":"Jour","year":"2016","journal-title":"J. Cutan Pathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1159\/000514806","article-title":"A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder","volume":"14","author":"Wang","year":"2021","journal-title":"Case Rep. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"588582","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jdermsci.2013.12.001","article-title":"Update on the pathogenesis of bullous pemphigoid: An autoantibody-mediated blistering disease targeting collagen XVII","volume":"73","author":"Nishie","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/CMR.0000000000000500","article-title":"Anti-programmed cell death-1 therapy-associated bullous disorders: A systematic review of the literature","volume":"28","author":"Zhao","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic Pemphigus Revealed by Anti-programmed Death-1 Pembrolizumab Therapy for Cutaneous Squamous Cell Carcinoma Complicating Hidradenitis Suppurativa","volume":"6","author":"Yatim","year":"2019","journal-title":"Front. Med."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Deshpande, R.P., Sharma, S., and Watabe, K. (2020). The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers, 12.","DOI":"10.3390\/cancers12102983"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/792\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:13:55Z","timestamp":1760134435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":131,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030792"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030792","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,4]]}}}